Opdivo and Hyperthyroid - a phase IV clinical study of FDA data

Summary:

Hyperthyroid is reported as a side effect among people who take Opdivo (nivolumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Yervoy, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Hyperthyroid when taking Opdivo. It is created by eHealthMe based on reports of 56,294 people who have side effects when taking Opdivo from the FDA, and is updated regularly.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.

What is Hyperthyroid?

Hyperthyroid is found to be associated with 1,144 drugs and 1,400 conditions by eHealthMe. Check the latest studies of Hyperthyroid.

On Oct, 13, 2025

56,294 people reported to have side effects when taking Opdivo.
Among them, 494 people (0.88%) have Hyperthyroid.

Among these 494 people:

How long have people been on Opdivo when they have Hyperthyroid? *

What is the gender of people who have Hyperthyroid when taking Opdivo? *

female: 37.23 %
male: 62.77 %

What is the age of people who have Hyperthyroid when taking Opdivo? *

What are other drugs people take besides Opdivo? *

What are other side effects people have besides Hyperthyroid? *

Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 127 people, 25.71%
Malignant Neoplasm Progression (cancer tumour came back): 52 people, 10.53%
Fever: 51 people, 10.32%
Adrenal Insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids): 50 people, 10.12%
Rashes (redness): 49 people, 9.92%
Diarrhea: 47 people, 9.51%
Thyroiditis (inflammation of thyroid gland): 47 people, 9.51%
Malaise (a feeling of general discomfort or uneasiness): 43 people, 8.70%
Hepatic Function Abnormal: 37 people, 7.49%
Nausea (feeling of having an urge to vomit): 34 people, 6.88%

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 101 people, 20.45%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 86 people, 17.41%
Lung Cancer - Non-Small Cell (lung cancer): 58 people, 11.74%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 45 people, 9.11%
Renal Cell Carcinoma (a kidney cancer): 42 people, 8.50%
Gastric Cancer (stomach cancer): 29 people, 5.87%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 18 people, 3.64%
Lung Neoplasm Malignant (cancer tumour of lung): 15 people, 3.04%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 13 people, 2.63%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 11 people, 2.23%

* Approximation only. Some reports may have incomplete information.

Do you take Opdivo and have Hyperthyroid?

- Check whether Hyperthyroid is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Opdivo:

Opdivo (56,331 reports)

Hyperthyroid treatments and more:

Hyperthyroid (26,827 reports)

Common Opdivo side effects:

Browse all side effects of Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common drugs associated with Hyperthyroid:

Browse all the drugs that are associated with Hyperthyroid:

Hyperthyroid (1,144 drugs)

Common conditions associated with Hyperthyroid:

Atrial fibrillation/flutter: 1,072 reports
Hypothyroidy: 958 reports
Hypertension aggravated: 904 reports
Hbp: 900 reports
Multiple sclerosis aggravated: 693 reports
Malignant melanoma: 553 reports
Pain: 444 reports
Osteoporosis: 434 reports
Alternative medicine - pain relief: 433 reports
Thin bones: 423 reports

Browse all the conditions that are associated with Hyperthyroid:

Hyperthyroid (1,400 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nivolumab (the active ingredients of Opdivo) and Opdivo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.